Sagimet Biosciences Inc. Balance Sheet
SGMT|2 years of annual SEC 10-K data (FY2023-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$160M
FY2024
Cash
$76M
Cash and equivalents
Total Debt
N/A
FY2024
Shareholder Equity
$91M
FY2024
Sagimet Biosciences Inc. had $160M in total assets and $91M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| Cash & Equivalents | $75.8M | $75.1M |
| Current Assets | $152.8M | $96.6M |
| Total Assets | $160.3M | $96.7M |
| Current Liabilities | $4.5M | $5.7M |
| Shareholders' Equity | $91.1M | -$186.9M |